Table of Contents
Thrombosis
Volume 2015 (2015), Article ID 414523, 6 pages
http://dx.doi.org/10.1155/2015/414523
Clinical Study

Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study

1Northwestern Memorial Hospital, 251 E. Huron Street, Chicago, IL 60611, USA
2Seton Northwest Hospital, 11113 Research Boulevard, Austin, TX 78759, USA
3University Medical Center Brackenridge, 601 East 15th Street, Austin, TX 78701, USA
4Seton Medical Center Williamson, 201 Seton Parkway, Round Rock, TX 78665, USA
5Seton Medical Center Austin, 1201 West 38th Street, Austin, TX 78705, USA

Received 28 August 2015; Accepted 6 December 2015

Academic Editor: Cees Vermeer

Copyright © 2015 Kirsten M. Roberts et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Trials have shown that novel oral anticoagulants may decrease length of stay versus warfarin. A comparison of length of stay in the treatment of pulmonary embolism (PE) has not been performed outside post hoc analysis of a large clinical trial. Objective. To evaluate if rivaroxaban decreases length of stay compared to warfarin plus enoxaparin in the treatment of PE. Methods. This was a multicenter, retrospective, observational cohort study. Patients were identified based on discharge diagnosis of PE and were excluded if they received anticoagulants prior to admission and had additional indications for anticoagulation or reduced creatinine clearance. The primary endpoint was length of stay. Secondary endpoints included time from initial dose of oral anticoagulant to discharge and length of stay comparison between subgroups. Results. Inclusion criterion was met by 158 patients (82 warfarin, 76 rivaroxaban). The median length of stay was 4.5 days (interquartile range [IQR], 2.7, 5.9) in the warfarin group and 1.8 days (IQR, 1.2, 3.7) in the rivaroxaban group (). Time interval from first dose of oral anticoagulant to discharge was shorter with rivaroxaban (). Conclusions. Patients given rivaroxaban had decreased length of stay versus those given warfarin plus enoxaparin for the treatment of PE.